The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N(G)-nitro-L-arginine methyl ester and L-arginine.
Boban-Blagaic. Alenka A; Blagaic. Vladimir V; Romic. Zeljko Z; Jelovac. Nikola N; Dodig. Goran G; Rucman. Rudolf R; Petek. Marijan M; Turkovic. Branko B; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 (10 µg/kg) dramatically lowered acute alcohol intoxication severity and mortality in mice.
- The peptide also reduced seizure‑type withdrawal symptoms after a 13‑day alcohol regimen.
- BPC‑157’s actions interact with the nitric‑oxide pathway; combining it with NO‑modulators (L‑arginine or L‑NAME) changes the outcomes.
Practical Outcomes
- The results hint that BPC‑157 might one day be used to lessen hangover‑like effects or alcohol‑withdrawal issues, but the data are only from mice and no human dosing is known. Biohackers should view this as an interesting lead, not a ready‑to‑use protocol, and await human trials before trying it for alcohol‑related benefits.
Summary
In a mouse study, a tiny protein called BPC‑157 helped protect against the worst parts of a big alcohol dose and reduced severe withdrawal seizures. It worked quickly, cutting down things like loss of right‑side‑up reflex, extreme cold, and even death. The peptide’s effects seemed linked to the body’s nitric‑oxide system, which can be tweaked with other compounds.
Abstract
Alcohol disturbances, NO stimulation (by the NO-precursor L-arginine), and/or NO-synthesis blockade (by N(G)-nitro-L-arginine methyl ester, i.e. L-NAME) were challenged with stable gastric pentadecapeptide BPC 157, which inhibits both acute alcohol intoxication and alcohol withdrawal symptoms. Mice received intraperitoneally (i.p.) BPC 157 (10 microg/kg), L-NAME (10 mg/kg), and L-arginine (400 mg/kg), alone or in combination, 5 minutes before or after acute ethanol (4 g/kg i.p.) intoxication or after 0, 3, or 7 hours of withdrawal after drinking 20% alcohol for 13 days. BPC 157 rapidly opposes the strongest disturbance presentations in acute intoxication (sustained ethanol anesthesia, complete loss of righting reflex, no reaction to external stimuli, hypothermia, 25% mortality) and withdrawal (prominent seizures). NO-agents: Aggravation of acute alcohol intoxication and opposition to withdrawal are common, but the later intervals affected by L-arginine and the action throughout the experiment by L-NAME are distinctive. Given together, L-arginine and L-NAME counteract each other, while either the "L-NAME presentation" (acute intoxication) or the "L-arginine presentation" (withdrawal) predominates. BPC157+NO-agent: In acute intoxication (L-NAME predominating in NO-system functioning to aggravate intoxication), both BPC157+L-NAME and BPC157+L-arginine follow the presentation of L-NAME, but without worsened mortality. In withdrawal (L-arginine predominating in NO-system functioning to oppose disturbance symptoms), BPC157+L-NAME follows the presentation of L-NAME, while BPC 157+L-arginine imitates that of L-arginine. The relationships among pentadecapeptide BPC 157, the NO-system, acute alcohol intoxication, and opposed withdrawal may be important, presenting pentadecapeptide BPC 157 as a suitable alcohol antagonist.
Study Information
pubmed
2005
2005-12-19T00:00:00.000Z